ReviewJournal of diabetes and metabolic disorders2026
Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight loss and metabolic benefits in overweight and obese populations. However, their cardio-metabolic efficacy and safety profile in Chinese adults remain incompletely characterized. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1RAs or dual GLP-1/GIP receptor agonists with placebo in overweight or obese Chinese adults. Searches were performed in PubMed, Cochrane CENTRAL, and Scopus from inception to October 12, 2025. Outcomes included changes in body weight, waist circumference, HbA1c, fasting glucose, cholesterol, systolic and diastolic blood pressure, and adverse events. Effect sizes were pooled using random-effects models and reported as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Results: Five RCTs comprising 2,204 participants were included, of whom 1,522 received GLP-1RA therapy and 682 received placebo. GLP-1RAs significantly reduced body weight (MD: -10.06 kg; 95% CI: -15.56 to - 4.56), waist circumference (MD: -7.06 cm; 95% CI: -9.85 to - 4.26), HbA1c (MD: -0.41%; 95% CI: -0.56 to - 0.27), fasting glucose (MD: -0.48 mmol/L; 95% CI: -0.69 to - 0.27), cholesterol (MD: -7.95 mg/dL; 95% CI: -9.57 to - 6.33), systolic blood pressure (MD: -4.26 mmHg; 95% CI: -6.28 to - 2.23), and diastolic blood pressure (MD: -2.44 mmHg; 95% CI: -3.70 to - 1.18). GLP-1RAs were associated with increased risks of gastrointestinal adverse events, including nausea, diarrhea, and vomiting, but not serious adverse events. Conclusion: Among overweight or obese Chinese adults, GLP-1RAs produce clinically significant improvements in body weight and multiple cardiometabolic risk factors while maintaining an acceptable safety profile. These findings support the role of GLP-1RAs as effective long-term therapeutic options for metabolic risk reduction in this population. Clinical Trial Registration: Not applicable. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-026-02000-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.